As the 67th American Society of Hematology (ASH) Annual Meeting approaches, the global hematology community will once again focus on the latest breakthroughs from China's innovative pharmaceutical companies. The 2025 American Society of Hematology (ASH) Annual Meeting will be held in Orlando, Florida, USA, from December 6 to December 9 local time, and the regular abstracts have already been published.

Qilu Pharmaceutical willNext-Generation Product Unveiled for the First Time at This ConferenceGPRC5D×BCMA×CD3 Three AntibioticsQLS4131InPreliminary Results of the First-in-Human Trial in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).

Screenshot source: ASH official website

QLS4131YesQilu PharmaceuticalA self-developed trispecific humanized antibody, its uniqueness lies in simultaneously targetingBCMA, GPRC5D and CD3. This design ingeniously addresses two core challenges in the current treatment of multiple myeloma:Tumor Antigen Heterogeneity and Immune Escape.

Screenshot source: Mosentropy Global Drug R&D Database

In traditional bispecific antibody drugs, the downregulation or loss of a single tumor target often leads to treatment resistance. AndQLS4131It is a trivalent architecture of BCMA/GPRC5D/CD3, achieving "dual locking" of MM cells: BCMA and GPRC5D are widely expressed on malignant plasma cells but exhibit individual variations. Simultaneously targeting these two antigens covers a broader population of MM patients and reduces the risk of drug resistance caused by the loss of a single antigen. The CD3 arm effectively activates T cells, forming "tumor cell-T cell" immune synapses and inducing potent tumor cell killing effects.

Source of screenshot: Mosentropy Global Drug R&D Database

Preclinical data show that, compared with competing products,QLS4131It exhibits higher affinity for multiple myeloma tumor cell lines, effectively eliminating double-positive tumor cells expressing both BCMA and GPRC5D, while also demonstrating potent killing effects on subpopulations expressing only one of the antigens. More notably, its tumor cell-killing activity is significantly higher than that of the comparator, providing strong preclinical evidence for clinical efficacy.

In addition,Qilu PharmaceuticalAnnounced in May 2025,QLS4131The expansion of indications from the oncology field to clinical trials for autoimmune diseases has also been approved. This "cross-field" layout reveals the broad application prospects of tri-specific antibody technology — by targeting specific B-cell subsets to eliminate pathogenic autoantibodies, it can theoretically be applied to various refractory autoimmune diseases such as systemic lupus erythematosus and myasthenia gravis, providing new hope for...QLS4131Open up growth space.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Trends in Clinical Trials in China and the Outlook for International Multicenter Clinical Trials - 202505

2024 Pharmaceutical Enterprise Comprehensive Strength Ranking - 202505

Analysis Report on China's Herpes Zoster Vaccine Industry - 202505

2023H2-2024H1 Analysis Report on Pharmaceuticals in China - 202504

Data Perspective: Application, Approval, and Sales of Innovative Traditional Chinese Medicine, Classic Prescriptions, Improved New Drugs, and Same-name Same-formula Products - 202503

2024 China Class 1 New Drug Targets White Paper - 202503

Top 100 List of Innovative Development of AI Healthcare Enterprises in China - 202502

Decoding Skincare Anti-Aging: Consumer Preference Insights and Market Landscape Analysis - 202502

Analysis Report on New Drugs Approved by the FDA for Marketing in 2024 - 202501

Small Molecule Chemical Drugs White Paper (Part I) - 202501

2024 China Healthcare Investment and Financing Panorama Insights Report - 202501

2024 Medical Insurance Negotiation and Market Analysis Report - 202501

More RecentlyMoxie ConsultingPopular Report, Scan the QR Code Below to Claim

Contact us to experience more professional services from Mosen Pharma.
WillDiscussion ConcordMade	GardenDistrict TakeService	Database Consultation	Customized Service	Media Cooperation

ClickImage Above, you can start the Mosentropy chemical data query

ClickReadRead the Original Text, apply for a free trial of MosEntropy Pharma Enterprise Edition!